A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

NCT05708950 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

314

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Solid Tumor
Melanoma
Carcinoma
Sarcoma
Lung Cancer
Prostate Cancer
Breast Cancer
Colo-rectal Cancer
Uterine Cancer
Pancreatic Cancer
Gastric Cancer
Esophageal Cancer
Thyroid Cancer
Ovarian Cancer
Kidney Cancer
Head and Neck Cancer

Interventions

DRUG: KVA12123 - Dose Escalation
DRUG: KVA12123 Plus Pembrolizumab - Dose Escalation
DRUG: KVA12123 - Dose Expansion
DRUG: KVA12123 Plus Pembrolizumab - Dose Expansion

Sponsor

Kineta Inc.

Collaborators

[object Object]